

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

**華康生物醫學控股有限公司**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock Code: 8622)**

### **PROFIT WARNING**

This announcement is made by Huakang Biomedical Holdings Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong.

Based on the information currently available to the board (the “**Board**”) of directors (the “**Directors**”) of the Company, including the preliminary review of the latest unaudited consolidated management accounts of the Group, the Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group is expected to record a loss attributable to owners of the Company of approximately RMB11.6 million for the year ended 31 December 2020 (the “**Current Year**”) as compared with approximately RMB284,000 for the year ended 31 December 2019 (the “**Corresponding Year**”).

The Board believes that the increase in loss in the Current Year was mainly attributable to:

- (i) the decline in sales revenue in the markets within the People’s Republic of China (“**PRC**”) of approximately RMB4.3 million as since the outbreak of the novel coronavirus (COVID-19) epidemic (the “**Epidemic**”), a number of provinces and municipalities in the PRC have taken emergency public health measures and various actions to prevent the spread of the Epidemic, including crowd-control and/or stay-home policies or orders and in addition, the Epidemic also led the Group to halt productions and sales for around five weeks;
- (ii) recognition of equity-settled share option expenses for the share options granted on 9 April 2020 of approximately RMB2.7 million;
- (iii) recognition of one-off non-cash provision for impairment loss of approximately RMB2.6 million which was recorded by the Group after it has performed an evaluation and assessment on the Group’s fixed assets and adopted the prudent principles in view of the adverse effect of the Epidemic on the business and operation environment ;
- (iv) the net foreign exchange loss of approximately RMB1.1 million, the majority of which was unrealized foreign exchange loss, due to fluctuations in the foreign exchange rate between foreign currency and RMB, compared to the net foreign exchange gain of approximately RMB498,000 in the Corresponding Year; and

- (v) the amount of impairment losses recognised on the Group's trade receivables of approximately RMB779,000 in the Current Year, compared to the reversal of impairment loss of approximately RMB250,000 in the Corresponding Year, which was mainly attributable to the Epidemic that affected the repayment abilities of the Group's debtors.

The Group has been closely monitoring the impact of the developments on the Group's businesses. As the duration of the Epidemic remains uncertain, the Group will continue to closely monitor the market conditions and will make appropriate measures in respect of the Epidemic's impacts on the financial positions and operation of the Group.

The information contained in this announcement is only based on the information currently available to the Board, including the preliminary review of the unaudited consolidated management accounts of the Group for the Current Year, which have not been audited or reviewed by the auditors of the Company or reviewed by the audit committee of the Company. Actual financial results for the Current Year may be different from what is disclosed in this announcement.

The Company is still in the process of finalising the Group's financial results for the Current Year. Shareholders and potential investors of the Company are advised to refer to the annual results announcement of the Company for the Current Year, which is expected to be published before the end of March 2021.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Shuguang**  
Chairman and Executive Director

Hong Kong, 5 March 2021

*As at the date of this announcement, the executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the independent non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Company Announcements" page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least seven days from the date of publication and on the Company's website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*